CA 19-9: Biochemical and clinical aspects

Advances in Experimental Medicine and Biology

Volumn 867, Issue , 2015, Pages 247-260

  Scarà, Salvatore ^a   Bottoni, Patrizia ^a   Scatena, Roberto ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Biomarker; CA 19 9; CA 19 9 biochemical structure; CA 19 9 measurement; Clinical interferences; DUPAN 2; Follow up pancreatic cancer; K ras; Methodological interferences; MIC 1; MicroRNA; Pancreatic cancer; REG 4; Serum tumor markers; Sialylated Lewis a antigen

Indexed keywords

BRCA2 PROTEIN; CA 19-9 ANTIGEN; DUKE PANCREATIC MONOCLONAL ANTIGENTYPE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH DIFFERENTIATION FACTOR 15; K RAS PROTEIN; MUCIN 1; MUCIN 2; MUCIN 4; MUCIN 5AC; REGENERATING ISLET DERIVED 4; SIALYL LEWIS X ANTIGEN; SMAD PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ANTIGEN FUNCTION; ANTIGEN STRUCTURE; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CELL SURFACE; HUMAN; IMMUNOASSAY; MOLECULAR DIAGNOSIS; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; BLOOD; CHEMISTRY; PANCREATIC NEOPLASMS;

CA-19-9 ANTIGEN; HUMANS; PANCREATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84946771471     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-94-017-7215-0_15     Document Type: Chapter

References (83)

1. Duffy MG, Sturgeon C, Lamerz R et al (2010) Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 21:441–447
2. Koprowski H, Steplewski Z, Mitchell K et al (1979) Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 5:957–971
3. Koprowski H, Herlyn M, Steplewski Z, Sears HF (1981) Specifi c antigen in serum of patients with colon carcinoma. Science 212:53–55
4. Magnani JL, Brockhaus M, Smith DF et al (1981) A monosialoganglioside is a monoclonal antibody- defi ned antigen of colon carcinoma. Science 212:55–56
5. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V (1983) Identifi cation of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 43:5489–5492
6. Uhlenbruck G, van Meensel-Maene U, Hanisch FG, Dienst C (1984) Unexpected occurrence of the Ca 19-9 tumor marker in normal human seminal plasma. Hoppe Seylers Z Physiol Chem 365:613–617
7. Goonetilleke KS, Siriwardena AK (2007) Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33:266–270
8. Daniels G (1995) Human blood groups. Blackwell Science Ltd., Oxford
9. Kannagi R (2002) Regulatory roles of carbohydrate ligands for selectins in the homing of lymphocytes. Curr Opin Struct Biol 12:599–608
10. Liu FT, Rabinovich GA (2010) Galectins: regulators of acute and chronic infl ammation. Ann N Y Acad Sci 1183:158–182
11. Crocker PR, Paulson JC, Varki A (2007) Siglecs and their roles in the immune system. Nat Rev Immunol 7:255–266
12. Hakomori S (1983) Tumor-associated glycolipid antigens defi ned by monoclonal antibodies. Bull Cancer 70:118–126
13. Hakomori S (1986) Tumor-associated glycolipid antigens, their metabolism and organization. Chem Phys Lipids 42:209–233
14. Hakomori S, Kannagi R (1983) Glycosphyngolipids as tumor-associated and differentiation markers. J Natl Cancer Inst (Bethesda) 71:231–251
15. Itai S, Nishikata J, Yoneda T et al (1991) Tissue distribution of sialyl 2–3 and 2–6 Lewis a antigens and the signifi cance of serum 2-3/2-6 sialyl Lewis a antigen ratio for the differential diagnosis of malignant and benign disorders of the digestive tract. Cancer (Phila) 67:1576–1587
16. Miyazaki K, Ohmori K, Izawa M et al (2004) Loss of disialyl Lewis a, the ligand for lymphocyte inhibitory receptor siglec-7, associated with increased sialyl Lewis a expression on human colon cancers. Cancer Res 64:4498–4505
17. Izawa M, Kumamoto K, Mitsuoka C et al (2000) Expression of sialyl 6-sulfo Lewis x is inversely correlated with conventional sialyl Lewis x expression in human colorectal cancer. Cancer Res 60:1410–1416
18. Miyazaki K, Sakuma K, Kawamura YI et al (2012) Colonic epithelial cells express specifi c ligands for mucosal macrophage immunosuppressive receptors siglec-7 and -9. J Immunol 188:4690–4700
19. Galli C, Basso D, Plebani M (2013) CA 19-9: handle with care. Clin Chem Lab Med 51:1369–1383
20. Basso D, Fabris C, Del Favero G et al (1990) How does liver dysfunction infl uence serum CA 19-9 in pancreatic cancer? Ital J Gastroenterol 22:1–6
21. Fabris C, Basso D, Piccoli A et al (1991) Role of local and systemic factors in increasing serum glycoprotein markers of pancreatic cancer. J Med 22:145–156
22. Basso D, Meggiato T, Fabris C et al (1992) Alterations in bilirubin metabolism during extra- and intrahepatic cholestasis. Clin Investig 70:49–54
23. Rothenberg ML, Abbruzzese JL, Moore M et al (1996) A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 78:627–632
24. Albert MB, Steinberg WM, Henry JP (1988) Elevated serum levels of tumor marker CA 19-9 in acute cholangitis. Dig Dis Sci 33:1223–1225
25. Duffy MJ (2007) Role of tumor markers in patients with solid cancers: a critical review. Eur J Intern Med 18:175–184
26. Steinberg W (1990) The clinical utility of the CA 19-9 tumor associate antigen. Am J Gastroenterol 85:350–355
27. Kim JE, Lee KT, Lee JK et al (2004) Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 19:182–186
28. Chang CY, Huang SP, Chiu HM et al (2006) Low effi - cacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan. Hepatogastroenterology 53:1–4
29. Kim HR, Lee CH, Kim YW et al (2009) Increased CA 19-9 level in patients without malignant disease. Clin Chem Lab Med 47:750–754
30. Kim YC, Kim HJ, Park JH et al (2009) Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? J Gastroenterol Hepatol 24:1869–1875
31. Ventrucci M, Pozzato P, Cipolla A, Uomo G (2009) Persistent elevation of serum CA 19-9 with no evidence of malignant disease. Dig Liver Dis 41:357–363
32. Sakahara H, Endo K, Nakajima K et al (1986) Serum CA 19-9 concentrations and computed tomography fi ndings in patients with pancreatic carcinoma. Cancer 57:1324–1326
33. Frebourg T, Bercoff E, Manchon N et al (1988) The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer 62:2287–2290
34. Fabris C, Del Favero G, Basso D et al (1988) Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach. Am J Gastroenterol 83:549–553
35. National Health Insurance Corporation (2000) National health insurance statistical yearbook 1999, 21:350–563
36. La’ulu SL, Roberts WL (2007) Performance characteristics of fi ve automated CA 19-9 assays. Am J Clin Pathol 127:436–440
37. Hotakainen K, Tanner P, Alfthan H et al (2009) Comparison of three immunoassays for CA 19–9. Clin Chim Acta 400:123–127
38. Deinzer M, Faissner R, Metzger T et al (2010) Comparison of two different methods for CA19-9 antigen determination. Clin Lab 56:319–325
39. Passerini R, Cassatella MC, Boveri S et al (2012) The pitfalls of CA 19–9: routine testing and comparison of two automated immunoassays in a reference oncology center. Am J Clin Pathol 138:281–287
40. Sturgeon C, Dati F, Duffy MJ et al (1999) Quality requirements and control: EGTM recommendations. Anticancer Res 19:2785–2820
41. Biguet B, Habersetzer F, Beaudonnet A et al (1995) Discordant CA 19.9 serum results by microparticle enzyme immunoassay and immunoradiometric assay. Clin Chem 41:1057–1058
42. Berth M, Bosmans E, Everaert J et al (2006) Rheumatoid factor interference in the determination of carbohydrate antigen 19-9 (CA 19-9). Clin Chem Lab Med 44:1137–1139
43. Liang Y, Yang Z, Ye W et al (2009) Falsely elevated carbohydrate antigen 19-9 level due to heterophilic antibody interference but not rheumatoid factor: a case report. Clin Chem Lab Med 47:116–117
44. Troup S (2012) Analyte monographs alongside the National Laboratory Medicine Catalogue. The Association for Clinical Biochemistry and Laboratory Medicine, London
45. Gillen S, Schuster T, Meyer zum Büschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7, e1000267
46. Brentnall TA, Bronner MP, Byrd DR et al (1999) Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 131:247–255
47. Canto MIGM, Yeo CJ, Griffi n C, Axilbund JE et al (2003) Screening for pancreatic neoplasia in high risk individuals. Clin Gastroenterol Hepatol 2:606–621
48. Canto MI, Hruban RH, Fishman EK et al (2012) Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142:796
49. Canto MI, Harinck F, Hruban RH et al (2013) International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familiar pancreatic cancer. Gut 62:339
50. Konstantinou F, Syrigos KN, Saif MW (2013) Pancreatic cancer: what about screening and detection? Highlights from the “2013 ASCO Annual Meeting”, Chicago, 30 May–4 June 2013
51. Berger AC, Meszoely IM, Ross EA et al (2004) Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol 11:644–649
52. Smith RA, Bosonnet L, Ghaneh P et al (2008) Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg 25:226–232
53. Zhang S, Wang YM, Sun CD et al (2008) Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J Gastroenterol 14:3750–3753
54. Waraya M, Yamashita K, Katagiri H et al (2009) Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol 16:1231–1240
55. Ferrone CR, Finkelstein DM, Thayer SP et al (2006) Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 24:2897–2902
56. Kondo N, Murakami Y, Uemura K et al (2010) Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 17:2321–2329
57. Schlieman MG, Ho HS, Bold RJ et al (2003) Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 138:951–955
58. Montgomery RC, Hoffman JP, Riley LB et al (1997) Prediction of recurrence and survival by post resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 4:551–556
59. Willett CG, Daly WJ, Warshaw AL (1996) CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 172:350–352
60. Halm U, Schumann T, Schiefke I et al (2000) Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 82:1013–1016
61. Maisey NR, Norman AR, Hill A et al (2005) CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 93:740–743
62. Takahashi H, Ohigashi H, Ishikawa O et al (2010) Serum CA19-9 alterations during preoperative gemcitabine- based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg 251:461–469
63. Bauer TM, El-Rayes BF, Li X et al (2013) Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer 119:285–292
64. Hernandez JM, Cowgill SM, Al-Saadi S et al (2009) CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. J Gastrointest Surg 13:349–353
65. Reni M, Cereda S, Balzano G et al (2009) Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 115:2630–2639
66. Ballehaninna UK, Chamberlain RS (2012) The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol 3:105–119
67. Jancík S, Drábek J, Radzioch D, Hajdúch M (2010) Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010:150960
68. Garcea G, Neal CP, Pattenden CJ et al (2005) Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 41:2213–2236
69. Er TK, Chen CC, Bujanda L, Herreros-Villanueva M (2014) Clinical relevance of KRAS mutations in codon 13: where are we? Cancer Lett 343:1–5
70. Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358:15–16
71. Talar-Wojnarowska R, Malecka-Panas E (2006) Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med Sci Monit 12:RA186–RA193
72. Wang Y, Gao J, Li Z et al (2007) Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profi le in endoscopic ultrasound-guided fi ne-needle aspiration specimens of the pancreas. Int J Cancer 121:2716–2722
73. Ringel J, Lohr M (2003) The MUC gene family: their role in diagnosis and early detection of pancreatic cancer. Mol Cancer 2:9
74. Moniaux N, Andrianifahanana M, Brand RE, Batra SK (2004) Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Br J Cancer 91:1633–1638
75. Yokoyama S, Kitamoto S, Higashi M et al (2014) Diagnosis of pancreatic neoplasms using a novel method of DNA methylation analysis of mucin expression in pancreatic juice. PLoS One 9, e93760
76. Senapati S, Gnanapragassam VS, Moniaux N (2012) Role of MUC4-NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells. Oncogene 31:3346–3356
77. Lee EJ, Gusev Y, Jiang J et al (2007) Expression pro- fi ling identifi es microRNA signature in pancreatic cancer. Int J Cancer 120:1046–1054
78. Wang J, Chen J, Chang P et al (2009) MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2:807–813
79. Humeau M, Torrisani J, Cordelier P (2013) miRNA in clinical practice: pancreatic cancer. Clin Biochem 46:933–936
80. Singh S, Chitkara D, Kumar V, Behrman SW, Mahato RI (2013) miRNA profi ling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 334:211–220
81. Liu J, Gao J, Du Y et al (2012) Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 131:683–691
82. Wang WS, Liu LX, Li GP et al (2013) Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer. Cancer Prev Res (Phila) 6:331–338
83. Liu R, Chen X, Du Y et al (2012) Serum microRNA expression profi le as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 58:610–618